We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
+7.56%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$40.8B
AUM Growth
+$3.42B
(+9.2%)
Cap. Flow
+$1.07B
Cap. Flow
% of AUM
2.63%
Top 10 Holdings %
Top 10 Hldgs %
25.28%
Holding
2,151
New
303
Increased
1,108
Reduced
653
Closed
86
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
West Pharmaceutical
WST
|
+$197M |
| 2 |
Walmart Inc
WMT
|
+$193M |
| 3 |
NextEra Energy
NEE
|
+$177M |
| 4 |
Apple
AAPL
|
+$129M |
| 5 |
UnitedHealth
UNH
|
+$120M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Qualcomm
QCOM
|
+$230M |
| 2 |
Sysco
SYY
|
+$164M |
| 3 |
Synopsys
SNPS
|
+$81.2M |
| 4 |
C.H. Robinson
CHRW
|
+$53.8M |
| 5 |
United Bankshares
UBSI
|
+$41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29.01% |
| 2 | Consumer Staples | 11.62% |
| 3 | Industrials | 10.88% |
| 4 | Consumer Discretionary | 9.53% |
| 5 | Healthcare | 9.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2001
LanzaTech
LNZA
$61.3M
| $40.3K | ﹤0.01% |
+211
| New | +$34.5K |
|
2002
Solid Power
SLDP
$468M
| $39.1K | ﹤0.01% |
28,934
+8,173
| +39% | +$12.9K |
|
2003
Organogenesis Holdings
ORGO
$308M
| $39K | ﹤0.01% |
+13,640
| New | +$38.3K |
|
|
CVAC
2004
DELISTED
CureVac
CVAC
| $39K | ﹤0.01% |
13,256
-591
| -4% | -$1.95K |
|
2005
Precigen
PGEN
$1.93B
| $38.8K | ﹤0.01% |
40,922
+7,707
| +23% | +$9.72K |
|
|
BHR
2006
Braemar Hotels & Resorts
BHR
$153M
| $38.5K | ﹤0.01% |
+12,454
| New | +$39.1K |
|
2007
ProKidney
PROK
$308M
| $37.7K | ﹤0.01% |
+19,629
| New | +$44.6K |
|
2008
Telos
TLS
$337M
| $37.4K | ﹤0.01% |
+10,407
| New | +$37.2K |
|
|
PSTX
2009
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $37.1K | ﹤0.01% |
+12,972
| New | +$40.2K |
|
2010
Trevi Therapeutics
TRVI
$2.49B
| $37.1K | ﹤0.01% |
+11,096
| New | +$33K |
|
2011
Atossa Therapeutics
ATOS
$22.8M
| $36.3K | ﹤0.01% |
+1,593
| New | +$32.2K |
|
|
CTV
2012
DELISTED
Innovid Corp.
CTV
| $36.2K | ﹤0.01% |
+20,129
| New | +$36.5K |
|
2013
iHeartMedia
IHRT
$535M
| $36.1K | ﹤0.01% |
19,527
+5,613
| +40% | +$8.36K |
|
2014
FuelCell Energy
FCEL
$1.7B
| $35.8K | ﹤0.01% |
3,143
+1,112
| +55% | +$16.5K |
|
2015
Compass Therapeutics
CMPX
$373M
| $35.5K | ﹤0.01% |
19,271
+7,048
| +58% | +$8.79K |
|
|
VTYX
2016
DELISTED
Ventyx Biosciences
VTYX
| $34.1K | ﹤0.01% |
15,659
+5,040
| +47% | +$11.6K |
|
2017
Chegg
CHGG
$108M
| $33.2K | ﹤0.01% |
18,760
+3,502
| +23% | +$8.58K |
|
|
FSP
2018
Franklin Street Properties
FSP
$44.8M
| $32.6K | ﹤0.01% |
+18,430
| New | +$30.6K |
|
2019
Accuray
ARAY
$28.4M
| $32.6K | ﹤0.01% |
18,121
+5,485
| +43% | +$10.4K |
|
|
SRTA
2020
Strata Critical Medical Inc
SRTA
$436M
| $32.2K | ﹤0.01% |
+10,964
| New | +$34.9K |
|
2021
GoPro
GPRO
$116M
| $32.2K | ﹤0.01% |
23,649
+6,745
| +40% | +$9.29K |
|
2022
Blink Charging
BLNK
$75.2M
| $31.3K | ﹤0.01% |
+18,179
| New | +$43.4K |
|
2023
Rackspace Technology
RXT
$1B
| $30.9K | ﹤0.01% |
+12,632
| New | +$30.5K |
|
2024
Dakota Gold
DC
$623M
| $30.1K | ﹤0.01% |
+12,770
| New | +$29.2K |
|
2025
Destination XL Group
DXLG
$34.7M
| $29.8K | ﹤0.01% |
+10,124
| New | +$31.5K |
|
Similar funds
ProShare Advisors's Q3 2024 Portfolio in Review
As of Q3 2024, ProShare Advisors held 2,151 positions worth $40.8B, up 9.2% from $37.4B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
ProShare Advisors's Q3 2024 filing shows 303 new, 1,108 increased, 653 reduced and 86 closed positions. Its largest new stake was NexPoint Residential Trust: 319,514 shares worth $14.1M. The largest sale was Qualcomm, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, down from 31% a quarter earlier, followed by Consumer Staples and Industrials.
- ProShare Advisors's largest Q3 2024 buy was NexPoint Residential Trust: 319,514 shares worth $14.1M.
- ProShare Advisors added most to West Pharmaceutical in Q3 2024, an estimated $197M increase.
- ProShare Advisors's biggest Q3 2024 reduction was Qualcomm, cutting an estimated $230M.
- ProShare Advisors fully exited Atrion Corp in Q3 2024, selling an estimated $8.02M.
- ProShare Advisors's ten largest holdings make up 25% of its $40.8B portfolio in Q3 2024.
- ProShare Advisors opened 303 new positions and closed 86 in Q3 2024.
- ProShare Advisors's portfolio value rose 9.2% quarter-over-quarter to $40.8B.
Based on ProShare Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.